Clinical Trial

A Phase 1 Study of HDM2017 in Advanced Solid Tumors

Name: A Phase 1 Study of HDM2017 in Advanced Solid Tumors — clinical trial record (NCT07274085)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of HDM2017 in patients with advanced malignant solid tumors.

Trial Details

NCT Number	NCT07274085
Lead Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions	Solid Tumors
Enrollment	96 participants
Start Date	2025-11-18
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-10